Cassava Sciences, Inc. announced that its lead drug candidate PTI-125 has been assigned the chemical drug name sumifilam by the United States Adopted Names (USAN) Council. Future references to PTI-125 will be sumifilam. A commercial brand name for sumifilam is expected to be announced at a future date. Sumifilam is an investigational new drug and has not been approved for any indication. Sumifilam is the first of a new class of drugs that bind filamin proteins. For this reason, USAN is expected to grant this class of drugs its own name stem -filam. Any future drug by any company that targets filamin protein is expected to incorporate the -filam name stem as part of its drug name.